A549 cell

Gefitinib

non-small cell lung cancer (NSCLC)

Clinical trial

Lung cancer

Cancer research

T790M

Environmental health

Epidermal growth factor receptor

Population

Internal medicine

Oncology

Medicine

Osimertinib

Cancer

Erlotinib

Annals of Oncology

Osimertinib was the first third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) to receive FDA and EMA approval for metastatic EGFR-mutant non-small-cell lung cancer (NSCLC) patients that have acquired the EGFR T790M resistance mutation. Clinical trials have demonstrated the efficacy of osimertinib in this patient population and clinical trials of other third-generation EGFR TKI are currently under way. Additional challenges in this patient population, such as the upfront efficacy of osimertinib, validation of T790M in liquid biopsies as a dynamic predictive marker of efficacy, along with combination with immune checkpoint inhibitors are being explored, representing an extraordinary time of development for EGFR-mutant NSCLC.

Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients